PSYENCE BIOMEDICAL LTD. (PBM) Form 6-K — Oct 21, 2026
Psyence BioMed (Nasdaq: PBM) completed a US$2,599,896 additional investment in PsyLabs after both backstop milestones were certified ahead of the December 31, 2026 deadline. The milestones were completion of an ibogaine regulatory readiness documentation package and execution of a U.S. cGMP manufacturing agreement with DEA-registered Benuvia Operations in Round Rock, Texas. The investment was priced at US$2,564 per share against a US$54 million pre-money valuation, lifting Psyence's stake in PsyLabs from approximately 41.13% to approximately 43.37%.
Key figures
- Debt Amount
- 0
- Backstop deadline
- 2026-12-31
- Backstop commitment usd
- 2600000
- Share price psy Labs usd
- 2564
- Pre investment stake pct
- 41.13%
- Additional investment usd
- 2599896
- Post investment stake pct
- 43.37%
- Psy Labs shares subscribed
- 1014
- Irrevocable commitment usd
- 2400000
- Psy Labs pre money valuation usd
- 54000000
- Definitive supply agreement deadline
- 2026-11-30
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.